NICE backs new treatment option for psoriasis
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
Read More
Tag: Skilarence
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
